Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multi Vessel Coronary Artery Disease Clear all
Completed No phase listed Observational Results available

Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care

NCT00783302
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 4 Interventional

Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty

NCT00162357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Restenosis
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Hartford, Connecticut • Waterbury, Connecticut • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 24, 2026, 5:19 PM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated No phase listed Observational

VitalScan MCG Rule-out Multi-centre Pivotal Study - US

NCT03546933
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
VitalScan Magnetocardiograph
Device
Lead sponsor
Creavo Medical Technologies Ltd
Industry
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Indianapolis, Indiana • Winston-Salem, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Multi-modality Imaging in Acute Myocardial Infarction

NCT02926755
View directory record Official record
Conditions
Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery
Interventions
Coronary Angiography
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 24, 2026, 5:19 PM EDT
Not yet recruiting Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

NCT07118449
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
XC001, A195/placebo
Drug
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 24, 2026, 5:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels

NCT00371748
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express2, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 3 Interventional

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

NCT01848106
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
pegnivacogin/anivamersen, Bivalirudin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 24, 2026, 5:19 PM EDT
Not yet recruiting No phase listed Observational

Analysis of ECGio to Predict Coronary Stenosis Against a Mixed Reference Standard

NCT07375810
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
AI-ECG Analysis
Device
Lead sponsor
Heart Input Output Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

NCT03400488
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AZD5718 oral suspension, Placebo matching AZD5817 oral suspension
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jul 24, 2026, 5:19 PM EDT
Enrolling by invitation No phase listed Observational

Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence

NCT06398366
View directory record Official record
Conditions
Cryptogenic Stroke
Interventions
Not listed
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

The MASS COMM Post-Randomization Phase Cohort Study

NCT02072421
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PCI
Procedure
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
2,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Brockton, Massachusetts • Framingham, Massachusetts • Lawrence, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

NCT00907998
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Anniston, Alabama • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Jul 24, 2026, 5:19 PM EDT
Recruiting No phase listed Observational

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

NCT05185492
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
STAVROS G DRAKOS
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Weston, Florida • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions
Single arterial graft, Multiple arterial grafting
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Withdrawn Phase 2 Interventional

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

NCT01770613
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
Interventions
Stem cells
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Gilbert, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 24, 2026, 5:19 PM EDT
Completed No phase listed Observational

CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study

NCT02694861
View directory record Official record
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Jul 24, 2026, 5:19 PM EDT
Withdrawn No phase listed Observational

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

NCT01085162
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jul 24, 2026, 5:19 PM EDT